Path 01
Clinical-stage targeted therapy
A non-toxic, clinical-stage approach for solid tumors expressing voltage-gated sodium channels. Available through partner clinics. Eligibility verified case-by-case.
Review the therapyIndependent patient resource
More options exist for advanced cancer.
For patients with stage 3 and stage 4 solid tumor cancers who have run out of standard answers. Clinical-stage targeted therapies, second opinions, and access pathways. United States, Mexico, Australia.
3
Countries with partner clinics
12+
Solid tumor types eligible
0
Cytotoxic side-effect profile
Three paths forward
Real options when standard treatment runs out.
Most patients arrive after the third opinion. The path that fits you depends on tumor type, prior treatment, and how quickly you need to act.
Path 02
Second opinion and re-staging
A second read on pathology, imaging, and treatment history through an NCI-designated comprehensive cancer center or equivalent. Often changes the plan.
Request a consultationPath 03
Active clinical trials
A focused trial search filtered to your tumor type, biomarkers, and geography. Includes early-phase access programs and expanded-access pathways.
Get a trial searchPatient guide
A practical guide for advanced cancer treatment.
What to do, in what order, when conventional treatment stops working.
What advanced cancer means
Advanced cancer covers stage 3 and stage 4 disease. Stage 3 disease has spread to regional lymph nodes or nearby tissue. Stage 4 disease has metastasized to distant organs. The treatment plan changes when standard first-line and second-line therapies stop producing durable response.
Most patients reach this point after a sequence of surgery, chemotherapy, radiation, and immunotherapy. The next conversation should center on three questions. What therapies remain that have not been tried. What clinical trials match the tumor profile. What targeted approaches are available outside the standard pathway.
The right question is not "what is next on the standard ladder." The right question is "what targeted option matches this specific tumor."
Targeted therapy in plain language
Targeted cancer therapy attacks specific molecular features of cancer cells. The features differ by tumor type. Some tumors over-express a surface receptor. Others over-express an ion channel. Targeted therapy uses that difference to selectively damage cancer cells while sparing normal tissue.
The clinical effect is two-fold. Therapeutic activity stays concentrated on the tumor. The side-effect burden drops compared with traditional cytotoxic chemotherapy. Patients report quality-of-life differences in the first treatment cycle.
Solid tumors that respond to targeted approaches
- Breast cancer including triple-negative subtypes
- Prostate cancer including castration-resistant disease
- Colorectal cancer including KRAS-mutant subtypes
- Lung cancer including non-small cell lung cancer
- Ovarian cancer
- Pancreatic cancer
- Melanoma and other skin cancers
- Gastric and esophageal cancers
Hematologic cancers and bone marrow primary cancers fall outside the scope of solid tumor targeted therapy. Patients in those categories should consult a hematologist-oncologist directly.
When to ask about non-toxic targeted therapy
Three patient situations should trigger a conversation about non-toxic targeted therapy.
- The cancer has progressed on two or more standard therapy lines.
- The patient cannot tolerate further cytotoxic therapy on clinical grounds.
- The patient wants to preserve treatment options for a future line of therapy.
The screening conversation takes about thirty minutes. The clinic reviews pathology, imaging, prior treatment, current performance status, and lab values. Eligibility is confirmed before scheduling.
Treatment access in the United States, Mexico, and Australia
Partner clinics operate in three jurisdictions today. The choice of jurisdiction depends on regulatory pathway, urgency, and the patient's clinical situation.
United States
Access in the United States runs through clinical trial enrollment, expanded-access programs, and the FDA Right-to-Try framework. Eligibility for expanded access requires documentation of serious or life-threatening disease, no comparable alternative, and a treating physician willing to administer the therapy.
Mexico
Mexican partner clinics offer faster access for international patients. The regulatory pathway is established and clinics operate under COFEPRIS oversight. Travel logistics are coordinated through the patient navigation team.
Australia
Australian clinics access the therapy through the Therapeutic Goods Administration's Special Access Scheme. The pathway is appropriate for stage 3 and stage 4 patients with documented progression on standard therapy.
Questions to ask your oncologist
- What molecular profiling has been done on the tumor?
- What targetable mutations or expression patterns are present?
- What clinical trials match the molecular profile?
- What expanded-access programs exist for this tumor type?
- How does the proposed next-line therapy compare with available targeted approaches?
How to get started
The first step is the consultation. The intake team requests pathology, recent imaging, and a treatment summary. The medical team reviews the file and confirms whether a targeted approach is clinically appropriate. The next conversation covers the right jurisdiction, the right partner clinic, and a realistic schedule.
No payment is required before clinical eligibility is confirmed.
Locations
Three jurisdictions, one coordinated network.
Partner clinics operate today in the United States, Mexico, and Australia. Additional jurisdictions in evaluation.
United States
Clinical trial, expanded access, Right-to-Try
Mexico
CORE Medical, Tijuana. COFEPRIS-regulated.
Australia
TGA Special Access Scheme
New jurisdictions
Under evaluation
Current U.S. Research
United States research, three centers.
Investigational research is currently conducted in the United States across three centers under physician leadership.
Research Site
Baton Rouge, Louisiana
U.S. investigational research
Research Site
New Orleans, Louisiana
U.S. investigational research
Research Site
Scottsdale, Arizona
U.S. investigational research
Investigators
Led by Dr. Pablo Prichard, M.D., and team.
Pablo Prichard, M.D.
Lead investigator. Leads the Vincere Foundation. Hosts the NBC series Forever Young, a health-and-longevity program where Dr. Prichard shares ongoing research, clinical perspectives, and healthcare innovation across episodes (Variety, 2025). Practice site: drprichard.com.
Larry Band, M.D.
Investigator.
Vershalee Shukla
Investigator.
Patient resources · Tijuana medical tourism
Independent guides for patients evaluating cross-border medical care in Tijuana, Mexico.
The procedure
How TOL is administered.
A two-component therapy: a cardiac glycoside drug to block sodium pumps, and a pulsed electric field device to open voltage-gated sodium channels. Cancer cells with 10 to 50 times the channel density of normal cells take in more sodium and water than they can handle, and rupture. Normal cells recover.
The three-step process.
Step 1
Diagnose, image, and dose
Biopsy and assay for voltage-gated sodium channel over-expression. If the patient is a candidate, image the tumor and begin oral dosing of digoxin six days before treatment.
Step 2
Treat in the device
The patient is placed in the Coaxial Ring device. Two hours on the first day, two hours on the second day, with a break halfway through each session. No sedation required.
Step 3
Gather data and treat again
Post-treatment biopsy and imaging. Compare to baseline. Plan additional courses two to three weeks apart based on response.
Procedure references: Device manufacturer: The Phantom Laboratory, Greenwich, NY. Full clinical detail and primary-source citations at FixCancer.org/procedure.
Patient stories
Real patient experiences with TOL.
First-person accounts from patients who have pursued Targeted Osmotic Lysis. We link to the original sources without editorial revision.
Rise for Lauren · December 2025
Targeted Osmotic Lysis
A patient narrative published by the Rise for Lauren foundation documenting one family's journey through TOL evaluation and treatment.
Read the full story →Tiffany Madison · Patreon
I Was Cancer (Part 1)
First-person essay from journalist Tiffany Madison documenting her cancer diagnosis and pursuit of Targeted Osmotic Lysis as a treatment path.
Read the essay →Sister site
The full clinical detail on the targeted therapy.
Mechanism, evidence, regulatory status, and the partner clinic network for the clinical-stage non-toxic targeted therapy that anchors this network.
Why FixCancers
Mechanism-targeted, not wellness-themed.
The therapy at the center of this network is Targeted Osmotic Lysis (TOL). It is a single mechanism, a documented regulatory pathway, and a named partner facility in Tijuana (CORE Medical). The clinical posture differs from the integrative wellness model that dominates cross-border cancer clinics. The comparison page covers mechanism, eligibility, evidence base, and regulatory posture side by side.
The mechanism, visualized
A single biological target. A two-component therapy.
Advanced solid tumors over-express voltage-gated sodium channels at 10 to 50 times normal cell density. TOL exploits that differential to selectively damage cancer cells while sparing healthy tissue.
Cell-scale comparison
The overexpression trap.
Normal cells stay stable. Cancer cells, carrying roughly fifty times the sodium channel density, take in water until membrane integrity fails.
The procedure
Five steps. No surgery. No chemo. No radiation.
The treatment is a five-stage protocol delivered over two consecutive days. Pre-treatment drug loading, two two-hour chamber sessions, and post-treatment imaging.
The science, in one view
Turning cancer's strength into a weakness.
The same VGSC over-expression that drives invasion and metastasis is the structural feature that makes the cell vulnerable. The science overview below covers the target, the three-step process, the selectivity, and the supporting evidence in one frame.
The evidence base
Thirteen peer-reviewed publications. One foundational patent.
Mechanism papers, preclinical models, human emergency-use case reports, veterinary safety studies, and independent reviews of voltage-gated sodium channel expression in cancer.
Frequently asked questions
What patients ask first.
Direct answers to the questions that arrive most often through the intake team.
What is targeted cancer therapy?
Targeted cancer therapy attacks specific molecular features of cancer cells rather than dividing cells in general. The approach reduces damage to healthy tissue and lowers the side-effect burden that defines traditional chemotherapy and radiation.
Are clinical-stage cancer therapies available outside of clinical trials?
Some clinical-stage cancer therapies are available through partner clinics in jurisdictions with established access frameworks for advanced therapies. Eligibility depends on tumor type, stage, prior treatment history, and overall clinical status. The intake team verifies eligibility before scheduling.
What cancers respond to non-toxic targeted therapy?
Solid tumor cancers expressing voltage-gated sodium channels are candidates for emerging non-toxic targeted therapies. Common candidate tumor types include breast, prostate, colorectal, lung, ovarian, pancreatic, gastric, and melanoma. Hematologic malignancies and bone marrow primary cancers are not candidates for this class of therapy.
How do I get a second opinion on a stage 4 cancer diagnosis?
Second opinions are available through academic medical centers, NCI-designated comprehensive cancer centers, and patient navigation services. Request your pathology slides, recent imaging, and treatment summary in advance. A second opinion changes the treatment plan in a meaningful number of cases.
How much does the consultation cost?
The initial consultation and eligibility review do not require payment. The team only discusses cost after clinical eligibility is confirmed and the patient has selected a jurisdiction and partner clinic.
How fast can treatment begin?
The screening conversation takes about thirty minutes. The clinical file review takes three to five business days. Treatment scheduling depends on the jurisdiction, the partner clinic, and the patient's logistics.
What is the difference between FixCancers.com and FixCancer.org?
FixCancers.com is the patient-facing education and access hub. FixCancer.org documents the clinical-stage targeted therapy in technical detail. Patients ready for the technical detail should visit FixCancer.org.
Start a consultation
Get a real answer in three to five business days.
Submit the intake. The clinical team reviews pathology, imaging, and treatment history. A clinician responds with a written eligibility assessment.
FixCancers.com is an independent patient resource. The site does not provide medical advice. The information presented here supports informed conversations between patients and their physicians. Eligibility for any therapy is determined by the treating clinical team.